Zacks Analyst Blog Highlights Eli Lilly, Costco, Morgan Stanley

The Zacks analyst blog highlighted four notable stocks: Eli Lilly (LLY), Costco (COST), Morgan Stanley (MS), and Kewaunee Scientific (KEQU). The report focused on Eli Lilly's expanding GLP-1 portfolio and pipeline, with strong demand ahead of its second-quarter earnings results.

Details

The report noted that Eli Lilly continues to expand its GLP-1 drug class, used for diabetes and obesity, with expectations of strong revenue growth. It also indicated that Costco and Morgan Stanley have solid fundamentals, while Kewaunee Scientific shows notable performance in its sector.

Context

This coverage comes as investors await Eli Lilly's Q2 results, with GLP-1 sales expected to be a key growth driver. Costco and Morgan Stanley represent defensive stocks amid market volatility.

What It Means for Investors

The report provides an overview of potential investment opportunities but does not offer a direct recommendation. Investors should conduct their own research and consider each company's fundamentals before making any decisions.